NEW

Masimo Announces iSirona Connectivity Hub

Masimo has announced the global launch of iSirona, a compact, versatile connectivity hub designed to maximize interoperability across the continuum of care.

DJO Acquires Trilliant Surgical

DJO LLC, a global provider of medical technologies to get and keep people moving, has announced the acquisition of Trilliant Surgical, a national provider of foot and ankle orthopedic implants.

DePuy Synthes Receives 510(k) FDA Clearance for VELYS™ Robotic-Assisted Solution Designed for Use with the ATTUNE Total Knee System

The Johnson & Johnson Medical Devices Companies announced that DePuy Synthes has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VELYS Robotic-Assisted Solution designed for use with the ATTUNE® Total Knee System and its cleared indications for use.

Philips to Acquire Capsule Technologies Inc.

Royal Philips has signed an agreement to acquire Capsule Technologies Inc., a provider of medical device integration and data technologies for hospitals and healthcare organizations.

Diversey Announces MoonBeam3 Effective Against SARS-CoV-2 in Seconds

Diversey, Inc. has received confirmation through third-party testing that MoonBeam3 UV-C disinfection technology is effective in just seconds against SARS-CoV-2, which causes COVID-19.

MoonBeam3 is an ultraviolet-C disinfection device that adds assurance beyond manual cleaning and disinfection. This portable, powerful solution disinfects quickly, reliably and responsibly. MoonBeam3 is cost-effective and designed for fast disinfection of public and high-risk areas. The system offers three individually adjustable arms that can be positioned at almost any angle, optimizing disinfection energy to allow dosing of both horizontal and vertical surfaces, in just 3 minutes.

MoonBeam3 has undergone third-party testing against several microorganisms including enveloped viruses, small non-enveloped viruses, bacteria and bacterial spores. These tests have demonstrated a significant log reduction in these key pathogens.

Since studies have shown that contamination of environmental surfaces in health care facilities with SARS-CoV-2 viral RNA is widespread, Diversey commissioned third-party testing of MoonBeam3 in the U.S., and has also partnered with the highly respected Fujita Health University in Japan, to test the effectiveness of the MoonBeam3 against SARS-CoV-2. The completed test results from Japan proved that MoonBeam3 was effective against SARS-CoV-2 under a range of conditions with contact times as low as 4 seconds for a 6-log reduction.

This study validates that MoonBeam3 is effective against SARS-CoV-2, the pathogen that causes COVID-19.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X